Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology's Annual Scientific Session
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, a pioneer in artificial heart technology, is set to showcase its advanced Emperor Total Artificial Heart at the upcoming American College of Cardiology (ACC) Annual Scientific Session in New Orleans, Louisiana, from March 28-30, 2026. This dedicated presentation, orchestrated by Engineering Project Manager Duffy Elmer, will take place on March 29, focusing on new preclinical findings that highlight the innovative features of the Emperor Total Artificial Heart.
This next-generation system, designed as a fully implantable electromechanical artificial heart, aims to retain the physiological autoregulation and hemodynamic performance that has characterized the existing SynCardia Total Artificial Heart (STAH) while facilitating long-term, fully implantable use. The Emperor initiative is positioned to enhance treatment modalities for patients suffering from advanced heart failure by potentially improving mobility and overall quality of life.
Throughout the ACC conference, SynCardia will host a booth (#2554) where attendees can engage with the company's engineering and clinical teams. This platform will inform medical professionals about the current clinical applications of the FDA-approved STAH and elucidate the developmental trajectory and vision for the Emperor Total Artificial Heart.
Mr. Elmer expressed confidence in the Emperor system, noting it as a significant evolution in heart therapy, intending to broaden treatment options for patients with severe biventricular heart failure. With over 2,100 implants and extensive clinical experience, SynCardia remains a leader in heart replacement technology, underlining its commitment to enhancing patient outcomes through innovative solutions. For more information, stakeholders are encouraged to visit the company’s website or review their regulatory filings with the U.S. Securities and Exchange Commission.
MWN-AI** Analysis
As Picard Medical, Inc. (NYSE American: PMI) prepares to present pivotal developments regarding its next-generation Emperor Total Artificial Heart at the upcoming American College of Cardiology’s Annual Scientific Session, investors should strategically evaluate the implications of this event for the company's stock performance and long-term prospects.
The Emperor Total Artificial Heart aims to address the critical need for advanced heart failure therapies by offering a fully implantable solution that retains physiological autoregulation, a feature that could significantly improve patient quality of life compared to existing therapies. The presentation of preliminary data at such a prestigious venue enhances the visibility of Picard Medical's innovation and reflects their commitment to advancing cardiac care. Given the growing emphasis on personalized and portable medical solutions in the healthcare sector, the Emperor's anticipated capabilities could strengthen Picard's market position and broaden its patient base.
Investors should closely monitor the feedback from the presentation and interactions at the ACC conference. Increased engagement from clinicians and researchers could translate to stronger interest in SynCardia’s technologies and heightened prospects for partnerships or sales agreements. Additionally, positive reception could bolster confidence in the company's growth trajectory leading up to potential future FDA approvals.
However, investors should remain vigilant about inherent risks associated with biotech investments, including regulatory hurdles and market competition from emerging technologies. If SynCardia successfully capitalizes on this momentum, it may drive stock prices higher in the following months. Conversely, any concerns revealed during presentations or discussions could negatively impact sentiment.
In conclusion, while Picard Medical presents a compelling investment opportunity driven by potential technological advancements, investors must consider market dynamics carefully and remain prepared for volatility surrounding clinical developments. Keeping abreast of the outcomes from the ACC conference will be crucial for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will be presenting a poster consisting of new preclinical data related to its next-generation Emperor Total Artificial Heart at the American College of Cardiology (ACC)’s Annual Scientific Session & Expo (ACC.26) to be held in New Orleans, Louisiana from March 28 to March 30, 2026.
Abstract Poster Presentation – ACC.26
- Title: THE EMPEROR TOTAL ARTIFICIAL HEART: A FULLY IMPLANTABLE, AUTOREGULATING SOLUTION FOR ADVANCED HEART FAILURE
- Date and Time: Sunday, March 29, 2026 | 11:00 a.m. – 12:00 p.m.
- Location: Posters, Hall E
- Presenter: Duffy Elmer, Engineering Project Manager, SynCardia LLC
The poster will present early engineering and preclinical evaluation of the Emperor Total Artificial Heart, which is being developed as a fully implantable electromechanical artificial heart system intended to preserve the physiological autoregulation and hemodynamic performance of the currently approved SynCardia Total Artificial Heart while enabling fully implantable operation.
Exhibition Information
At ACC.26, SynCardia will also exhibit at booth #2554 throughout the conference.
Conference attendees are invited to visit the booth to meet with SynCardia’s engineering and clinical teams, and to learn more about the FDA approved SynCardia Total Artificial Heart, including its clinical use as a bridge to transplant for patients with advanced biventricular heart failure. Company representatives will also be available to discuss the design, development progress, and future clinical direction of the fully implantable Emperor Total Artificial Heart platform. The Company’s participation in the conference will provide an opportunity for clinicians, researchers, and industry participants to learn about SynCardia’s current clinical technology as well as its next-generation artificial heart development program.
Mr. Elmer, Engineering Project Manager, SynCardia LLC and presenter at the conference, commented, “The Emperor Total Artificial Heart represents the next evolution in total artificial heart therapy. The system is being designed to combine a fully implantable architecture with physiologic autoregulation in order to preserve the proven hemodynamic performance of the SynCardia Total Artificial Heart while enabling fully implantable long-term support. By building on the reliability and clinical experience of the SynCardia platform, the Emperor program aims to expand treatment options and improve mobility and quality of life for patients with advanced heart failure. We look forward to informing clinicians about this at the upcoming ACC conference.”
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to leverage the new preclinical data on the Emperor Total Artificial Heart to attract potential investors at the ACC.26 conference?
What are the anticipated impacts of the fully implantable Emperor Total Artificial Heart on the market share of Picard Medical Inc. PMI in the advanced heart failure treatment segment?
Can you detail the expected timeline for clinical trials related to the Emperor Total Artificial Heart and how this might affect Picard Medical Inc. PMI's growth trajectory?
How does Picard Medical Inc. PMI intend to manage the risks associated with the development of the Emperor Total Artificial Heart while ensuring investor confidence during the process?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
-4.06% G/L:
$0.4821 Last:
552,836 Volume:
$0.46 Open:
